{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:40:48Z","timestamp":1789339248211,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union\u2019s Horizon Europe research and innovation programme","award":["project Prevalung EU, grant agreement number 101095604"],"award-info":[{"award-number":["project Prevalung EU, grant agreement number 101095604"]}]},{"name":"the China Scholarship Council","award":["201908070134"],"award-info":[{"award-number":["201908070134"]}]},{"name":"program France 2030 RHU","award":["ANR-23-RHUS-0010 LUCA-pi"],"award-info":[{"award-number":["ANR-23-RHUS-0010 LUCA-pi"]}]},{"name":"program France 2030 RHU","award":["ANR-21-RHUS-0017 IMMUNOLIFE"],"award-info":[{"award-number":["ANR-21-RHUS-0017 IMMUNOLIFE"]}]},{"name":"European Research Council Advanced Investigator Awards","award":["Grant No. 294604; project acronym ROBINSCA"],"award-info":[{"award-number":["Grant No. 294604; project acronym ROBINSCA"]}]},{"name":"European Research Council Advanced Investigator Awards","award":["ERC-2023-ADG, Grant No. 101142062; project acronym MADCAM"],"award-info":[{"award-number":["ERC-2023-ADG, Grant No. 101142062; project acronym MADCAM"]}]},{"name":"European Research Council Advanced Investigator Awards","award":["ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer, ERC-2023-ADG"],"award-info":[{"award-number":["ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer, ERC-2023-ADG"]}]},{"name":"European Union's Horizon 2020","award":["Grant No. 848294, project acronym: 4-IN-THE-LUNG-RUN"],"award-info":[{"award-number":["Grant No. 848294, project acronym: 4-IN-THE-LUNG-RUN"]}]},{"DOI":"10.13039\/501100004099","name":"Ligue contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the IdEx Universit\u00e9 de Paris Cit\u00e9","award":["ANR-18-IDEX-0001"],"award-info":[{"award-number":["ANR-18-IDEX-0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02507-3","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:44:28Z","timestamp":1764071068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Marine","family":"Fidelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Mont\u00e9gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boulate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Abdayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlijn M.","family":"van der Aalst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2507_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13910","volume":"22","author":"L Mont\u00e9gut","year":"2023","unstructured":"Mont\u00e9gut L, Abdellatif M, Moti\u00f1o O, Madeo F, Martins I, Quesada V, et al. Acyl coenzyme A binding protein (ACBP): An aging- and disease-relevant \u201cautophagy checkpoint.\u201d Aging Cell. 2023;22:e13910. https:\/\/doi.org\/10.1111\/acel.13910.","journal-title":"Aging Cell"},{"key":"2507_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07447-w","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Mingoia S, Mont\u00e9gut L, Lambertucci F, Chen H, Dong Y, et al. Atlas of expression of acyl CoA binding protein\/diazepam binding inhibitor (ACBP\/DBI) in human and mouse. Cell Death Dis. 2025;16:134. https:\/\/doi.org\/10.1038\/s41419-025-07447-w.","journal-title":"Cell Death Dis"},{"key":"2507_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03864-9","volume":"12","author":"A Joseph","year":"2021","unstructured":"Joseph A, Chen H, Anagnostopoulos G, Mont\u00e9gut L, Lafarge A, Moti\u00f1o O, et al. Effects of acyl-coenzyme A binding protein (ACBP)\/diazepam-binding inhibitor (DBI) on body mass index. Cell Death Dis. 2021;12:599. https:\/\/doi.org\/10.1038\/s41419-021-03864-9.","journal-title":"Cell Death Dis"},{"key":"2507_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207344119","volume":"119","author":"O Moti\u00f1o","year":"2022","unstructured":"Moti\u00f1o O, Lambertucci F, Anagnostopoulos G, Li S, Nah J, Castoldi F, et al. ACBP\/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. Proc Natl Acad Sci U S A. 2022;119:e2207344119. https:\/\/doi.org\/10.1073\/pnas.2207344119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2507_CR5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501584122","volume":"122","author":"L Mont\u00e9gut","year":"2025","unstructured":"Mont\u00e9gut L, Lambertucci F, Moledo-Nodar L, Fiuza-Luces C, Rodr\u00edguez-L\u00f3pez C, Serra-Rexach JA, et al. Acyl-CoA-binding protein as a driver of pathological aging. Proc Natl Acad Sci U S A. 2025;122:e2501584122. https:\/\/doi.org\/10.1073\/pnas.2501584122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2507_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13751","volume":"22","author":"L Mont\u00e9gut","year":"2023","unstructured":"Mont\u00e9gut L, Joseph A, Chen H, Abdellatif M, Ruckenstuhl C, Moti\u00f1o O, et al. High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: evidence for a phylogenetically conserved proaging function of ACBP. Aging Cell. 2023;22:e13751. https:\/\/doi.org\/10.1111\/acel.13751.","journal-title":"Aging Cell"},{"key":"2507_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02098-5","volume":"23","author":"L Mont\u00e9gut","year":"2024","unstructured":"Mont\u00e9gut L, Liu P, Zhao L, P\u00e9rez-Lanz\u00f3n M, Chen H, Mao M, et al. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Mol Cancer. 2024;23:187. https:\/\/doi.org\/10.1186\/s12943-024-02098-5.","journal-title":"Mol Cancer"},{"key":"2507_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102232","volume":"6","author":"S Li","year":"2025","unstructured":"Li S, Moti\u00f1o O, Lambertucci F, Pol J, Chen H, Pan L, et al. Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma. Cell Rep Med. 2025;6:102232. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102232.","journal-title":"Cell Rep Med"},{"key":"2507_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.62347\/COTC6463","volume":"14","author":"S Wang","year":"2024","unstructured":"Wang S, Wei D, Zhao Y, Pang X, Zhang Z. Development and validation of machine learning models for diagnosis and prognosis of cancer by urinary proteomics, based on the FLEMENGHO cohort. Am J Cancer Res. 2024;14:643\u201354. https:\/\/doi.org\/10.62347\/COTC6463.","journal-title":"Am J Cancer Res."},{"key":"2507_CR10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/ehjci\/jeaa168","volume":"21","author":"CM van der Aalst","year":"2020","unstructured":"van der Aalst CM, Denissen SJAM, Vonder M, Gratama JWC, Adriaansen HJ, Kuijpers D, et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. Eur Heart J Cardiovasc Imaging. 2020;21:1216\u201324. https:\/\/doi.org\/10.1093\/ehjci\/jeaa168.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2507_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067191","volume":"12","author":"D Boulate","year":"2022","unstructured":"Boulate D, Fidelle M, Caramella C, Issard J, Planch\u00e9 O, Prad\u00e8re P, et al. Epidemiological study to assess the prevalence of lung cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: prevalung study protocol. BMJ Open. 2022;12:e067191. https:\/\/doi.org\/10.1136\/bmjopen-2022-067191.","journal-title":"BMJ Open"},{"key":"2507_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622:348\u201358. https:\/\/doi.org\/10.1038\/s41586-023-06563-x.","journal-title":"Nature"},{"key":"2507_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2528955","volume":"14","author":"L Mont\u00e9gut","year":"2025","unstructured":"Mont\u00e9gut L, Rousseau A, Ungolo C, Derosa L, Fidelle M, Alves Costa Silva C, et al. Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. Oncoimmunology. 2025;14:2528955. https:\/\/doi.org\/10.1080\/2162402X.2025.2528955.","journal-title":"Oncoimmunology"},{"key":"2507_CR14","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41418-025-01474-y","volume":"32","author":"U Nogueira-Recalde","year":"2025","unstructured":"Nogueira-Recalde U, Lambertucci F, Mont\u00e9gut L, Moti\u00f1o O, Chen H, Lachkar S, et al. Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritis. Cell Death Differ. 2025;32:1484\u201398. https:\/\/doi.org\/10.1038\/s41418-025-01474-y.","journal-title":"Cell Death Differ"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02507-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02507-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:44:30Z","timestamp":1764071070000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02507-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02507-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FLEMENGHO, PREVALUNG and ROBINSCA studies are part of the European Union\u2019s Horizon Europe research and innovation programme under grant agreement number 101095604 - [project acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception]. The Flemish study on Environment, Genes and Health Outcomes (FLEMENGHO) study is a population-based cohort from northern Belgium, approved by the Ethics Committee of the University of Leuven (S64406). The PREVALUNG study is an epidemiological study to assess the prevalence of lung cancer in patients with smoking-associated atherosclerotic cardiovascular diseases. The study was approved according the French Jard\u00e9 Law; the study is referenced at the French 'Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9' (reference ID RCB: 2019-A00262- 55) and registered on clinicaltrial.gov (NCT03976804). Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) is a population-based randomized controlled screening trial from the Netherlands that investigates the effectiveness of CVD screening in asymptomatic participant and is registered under NTR6471. Written informed consent was obtained from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided their consent for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LM and GK are inventors of patents covering therapeutic targeting of ACBP\/DBI. GK is the founder of Osasuna Therapeutics.\u00a0LZ has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota.\u00a0GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, and Rejuveron Life Sciences\/Centenara Labs AG. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis, and metabolic disorders. GK\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}